Researchers involved in an international randomized Phase IIB study have reported that the combination of Nexavar® (sorafenib) and Taxol® (paclitaxel) improves progression-free survival (PFS) compared with Taxol plus placebo in patients with advanced or metastatic HER2-negative breast cancer. These results were presented at the 2009 San Antonio Breast Cancer Symposium.

This entry was posted on Saturday, December 19th, 2009 at 7:48 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.